Abvc Biopharma, Inc.
ABVC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173313
No open-market purchases or sales by Abvc Biopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.72M in total; no superinvestor holds it.
Other share classesECOC
Q2 2022 vs. Q1 2022
How the institutions holding Abvc Biopharma, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 4 | 5 | +1 |
| Shares | 427.8K | 1.56M | +1.14M (+265.3%) |
| Value | $1.17M | $1.66M | +$488.0K (+41.8%) |
New holders (3)
Institutions that held Abvc Biopharma, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 1,092,745 | $1.16M | 0.03% |
| BlackRock Inc. | 39,042 | $41.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 5,997 | $6.00K | 0.00% |
Sold out (2)
Institutions that held Abvc Biopharma, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Morgan Stanley | 1,460 | $4.00K |
| UBS Group AG | 1,274 | $3.00K |